FDA

For Doctors: How You Can Help Your Patients Who Are Running Out of HIV Treatment Options

By Nelson Vergel, B.S.Ch.E., M.B.A. July 6, 2011 In a previous blog post, I reviewed the current situation for the minority of patients with HIV who have run out of treatment options. Of the HIV medications in development with potential activity against highly resistant HIV (i.e., patients with GSS=0), two may become available within the next …

For Doctors: How You Can Help Your Patients Who Are Running Out of HIV Treatment Options Read More »

AIDS Activists Support the Approval of Egrifta- But With Some Conditions for Theratecnologies and Serono

17 May 2010 Paul Tran, BS Pharrn, RPh Advisors and Consultants Staff Center for Drug Evaluation and Research Food and Drug Administration 5630 Fishers Lane, HFD-21 Rockville, MD 20857 Dear Mr. Tran: On behalf ofthe Drug Development Committee (DDC) ofthe AIDS Treatment Activists Coalition (ATAC), I am writing to urge members ofthe Endocrinologic and Metabolic …

AIDS Activists Support the Approval of Egrifta- But With Some Conditions for Theratecnologies and Serono Read More »

The Forgotten Minority: HIV+ Patients With No Available HIV treatment Options

Most successful HIV medication combinations require 3 medications that are fully active, but a small portion of long term survivors with long treatment history and accumulated HIV resistance mutations do not have the luxury of constructing a viable regimen to save their lives. Several potent antiretrovirals (ARVs) in the past 4 years have enabled many …

The Forgotten Minority: HIV+ Patients With No Available HIV treatment Options Read More »